Page last updated: 2024-08-21

nsc 65346 and Pancreatic Neoplasms

nsc 65346 has been researched along with Pancreatic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bastea, LI; Döppler, HR; Hollant, LMA; Reid, EM; Storz, P	1

Other Studies

1 other study(ies) available for nsc 65346 and Pancreatic Neoplasms

Article	Year
Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. Scientific reports, 2019, 11-12, Volume: 9, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Histones; Humans; Intracellular Signaling Peptides and Proteins; Mice; Pancreatic Neoplasms; Phosphorylation; Prognosis; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrimidine Nucleosides; Signal Transduction; Survivin; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2019

Article

Year

Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.

Scientific reports, 2019, 11-12, Volume: 9, Issue:1

Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Histones; Humans; Intracellular Signaling Peptides and Proteins; Mice; Pancreatic Neoplasms; Phosphorylation; Prognosis; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrimidine Nucleosides; Signal Transduction; Survivin; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019